Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

Summary

The investigators hypothesize that pre-operative statin use is neuroprotective at maximal doses. The goals are to determine the safety, feasibility, and efficacy of maximizing statin doses for two weeks (12-18 days) prior to CEA using change in performance on a battery neuropsychometric tests as outcome measure. Study will recruit patients based on their preexisting statin regimen. The investigators hypothesize that in asymptomatic CEA patients: 1) Pre-operative statin use is neuroprotective against early cognitive dysfunction (eCD) and lowers the risk of early mortality. 2) Maximal doses may be essential in achieving optimal neuroprotection against eCD.

Timeline

Start

2017-06-01

Primary completion

2020-03-31

Completion

2020-03-31

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated early due to recruitment limitations, particularly difficulty enrolling statin-naïve patients”

Drugs

Indications